Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Jose M. Herranz
Vall d’Hebron Institute of Oncology (VHIO)
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
70
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Anticancer Activity of RAS-GTP Inhibition in Cholangiocarcinoma
Number of pages: 56
Posted: 04 Jul 2025
Rodrigo Entrialgo-Cadierno
,
Konstantina Morali
,
Iker Feliu
,
Yingyun Wang
,
Jim Evans
,
Mariana Yañez-Bartolome
,
Ines Lopez
,
Irati Macaya
,
Cristina Cueto-Ureña
,
Yaiza Senent
, Jose M. Herranz,
Rashi Raghulan
,
Javier Vaquero
,
Jesus Maria Banales
,
Teresa Macarulla
,
Mariano Ponz-Sarvise
,
Ximo Pechuan-Jorge
,
Elisabeth Guruceaga
,
Tian Tian
,
Ida Aronchik
,
Mallika Singh
,
Jingjing Jiang
,
Silvestre Vicent
and
Sneak Peek Administrator
University of Navarra, University of Navarra, University of Navarra, Revolution Medicines Inc, Revolution Medicines Inc, Vall d’Hebron Institute of Oncology (VHIO), University of Navarra, University of Navarra, University of Navarra, University of Navarra, Vall d’Hebron Institute of Oncology (VHIO), Revolution Medicines Inc, University of Salamanca - CSIC, Cancer Research Center, Biogipuzkoa Health Research Institute, Vall d’Hebron Institute of Oncology (VHIO), Universidad de Navarra - Clinica Universidad de Navarra and Program in Solid Tumors (CIMA), Revolution Medicines Inc, University of Navarra, Vall d’Hebron Institute of Oncology (VHIO), Revolution Medicines Inc, Revolution Medicines Inc, Revolution Medicines Inc, University of Navarra and Independent
Downloads
70
(883,195)
View PDF
Download
Abstract:
cholangiocarcinoma, KRAS oncogene, RAS-GTP inhibitors, resistance
Feedback
